Sanofi

Gaithersburg – November 05, 2026 -- Novavax raised its full-year 2026 Non-GAAP Adjusted Total Revenue guidance by $145 million to $400 million at the mid-point, after earning a $125 million milestone from partner Sanofi and cutting its quarterly net loss to $31 million from $202 million a year earlier.

Sanofi's European Phase 3 start triggers $125 million payment

Novavax earned the payment in October, when Sanofi initiated a Phase 3 trial of its influenza-COVID-19 combination (CIC) vaccine in Europe. Sanofi has confirmed it intends to start a U.S. Phase 3 CIC trial in 2027 to support U.S. approval.

BOSTON – November 04, 2026 -- Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index and placed in the top three in all three categories: research, clinical development and commercial. The rankings, developed with IDEA Pharma, a division of SAI MedPartners, were revealed on the CNS Summit 2026 main stage at Encore Boston Harbor.

Index ranks 30 pharma companies on public digital initiatives and investments

Now in its 11th year, the Index scores the top 30 pharmaceutical companies on digital innovation. It draws only on publicly reported initiatives and investments from July 2025 through July 2026.

The 2026 top 10 are Sanofi, Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA.

Roche, Novo Nordisk and Recursion lead individual categories

Roche led the commercial category and Novo Nordisk led clinical development. Recursion led research.

BOSTON – October 30, 2026 -- Nearly 150 million Americans now live in areas with unhealthy air quality, according to a new issue brief from nonprofit consultancy FSG that urges funders and policymakers to back community-led respiratory health programs.

The brief, titled "Improving Community Respiratory Health: Place-Based Lessons from the Field," was released in recognition of Lung Health Day. It draws on research and interviews with leaders from community-based organizations, philanthropy, healthcare and advocacy groups.

Six elements define effective place-based respiratory models

FSG identifies six common characteristics of successful models:

San Mateo, Calif. – September 25, 2026 -- Kali Therapeutics has been named one of the 11 most promising private biotechnology companies in the 2026 Endpoints 11, a list curated annually by Endpoints News editors from hundreds of private candidates.

Kali advanced two clinical candidates and closed a Sanofi licensing deal in just over two years

Founded in July 2024, the clinical-stage biotech moved from formation to two molecules in the clinic and a worldwide partnership with Sanofi inside roughly two years. The honorees were announced Thursday, September 24, 2026, at an awards gala at The State Room in Boston.

SHERIDAN, WYOMING - March 04, 2026 - Sanofi has signed a worldwide licensing agreement with Sino Biopharmaceutical to secure global exclusive rights to rovadicitinib, an investigational oral small molecule positioned as an anti-inflammatory and anti-fibrotic therapy. The transaction includes a $135 million upfront payment and gives Sanofi the exclusive right to develop, manufacture, and commercialize the product globally, while Sino Biopharm is eligible for up to $1.395 billion in clinical, regulatory, and sales milestones plus double-digit tiered royalties. Operationally, the deal adds an oral candidate with a defined mechanism to Sanofi's immunology buildout and extends a pattern of external sourcing designed to accelerate portfolio depth without waiting for internal discovery timelines.